Simple to Join, Hard to Miss – HTX Launches “Earn as You Borrow” Week for Traders to Capture Market Opportunities at Lower Cost
PANAMA CITY, Nov. 10, 2025 /PRNewswire/ -- HTX today announced the launch…
Redington Foundation joins hands with Protean VidyaSaarthi for 1 Crore+ Scholarship Program
₹ 1 crore+ commitment to fund education for 600+ students across India…
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification
Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume…
George Medicines presents long-term efficacy and safety data for single pill triple combination therapy for hypertension at American Heart Associations Scientific Sessions 2025
London, UK, Boston, MA, 9 November 2025 – George Medicines, a late-stage…
Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025
November 09, 2025 09:00 ET | Source: Medera Inc. BOSTON, Nov. 09,…
Louis Limited Sets New Standard for Trading Psychology With Dynamic Emotion Tracking Features
Louis Limited sets a new benchmark in trading psychology with a feature-rich…
AI Meets Digital Assets: CreditBlockchain Launches Free Cloud Trial for XRP Investors Era
New York, NY, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Credit Blockchain, a…
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025 11:45 ET | Source: Vor Biopharma Treatment with telitacicept…
Riyadh Opens Its Doors to the World: Biban 2025 Kicks Off as the Global Destination for Opportunities
RIYADH, Saudi Arabia, Nov. 6, 2025 /PRNewswire/ -- The Small and Medium…
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase…
